Jean-Marc Bellemin serves as the Chief Financial Officer at Iovance Biotherapeutics, Inc., a leading biotechnology company focused on developing novel cancer immunotherapies. With an extensive background in finance and the life sciences industry, Bellemin brings a wealth of experience to his role. Prior to joining Iovance, he held the position of CFO at several notable biotech firms, including Novocure, where he played a pivotal role in the company's growth and successful IPO. Bellemin's expertise in financial strategy and capital markets has been instrumental in guiding Iovance through its various stages of development. At Iovance, Bellemin is responsible for overseeing the company's financial operations, including financial planning and analysis, accounting, and investor relations. His strategic vision has been crucial in securing funding for Iovance's innovative research and development programs, which aim to bring new treatment options to patients with advanced cancers. Under his leadership, Iovance has successfully raised significant capital through public offerings and strategic partnerships, enabling the company to advance its pipeline of tumor-infiltrating lymphocyte (TIL) therapies. Bellemin's achievements extend beyond his role at Iovance. He has been recognized for his contributions to the biotechnology industry, receiving accolades for his financial acumen and leadership. His ability to navigate complex financial landscapes and drive growth has made him a respected figure in the field. As Iovance continues to progress towards its goal of transforming cancer treatment, Bellemin's expertise and dedication remain vital to the company's success.